-
JBCRG-13
A phase II study of metronomic paclitaxel + cyclophosphamide + capecitabine (PCX) followed by 5-fluorouracil + epirubicin + cyclophosphamide (FEC) as preoperative chemotherapy for triple negative or low hormone receptors/HER2 negative primary breast cancer.
- Status
-
Study Closed
- Objectives
-
To evaluate the efficacy and safety of metronomic paclitaxel + cyclophosphamide + capecitabine (PCX) followed by 5-fluorouracil, epirubicin + cyclophosphamide (FEC) as preoperative chemotherapy for triple negative or low hormone receptors/HER2 negative primary breast cancer.
- Subjects
-
- Endpoints
-
Primary endpoint：Pathological complete response rate Secondary endpoints：Overall response rate, Safety, Breast conservation rate, Overall surival, Disease-free survival
- Trial Period
-
Jan 2010-Dec 2012
Registration: 2 years
Follow-up: 5 years from LPI
- Lead Principal Investigator
-
Norikazu Masuda (Dept of Surgery, Osaka National Hospital)
- Target Sample Size
-
40
- Regimen
-
Metronomic PCX＋FEC
- Source of Funding
-
JBCRG
- Conference Presentation
-
A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer (JBCRG-13)
- Articles and Publications
-
A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer
- UMIN-ID
-
UMIN000003570
- jRCT
-
- Memo
-
- COI Disclosure
-
